BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19685112)

  • 21. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations.
    Brini M; Manni S; Pierobon N; Du GG; Sharma P; MacLennan DH; Carafoli E
    J Biol Chem; 2005 Apr; 280(15):15380-9. PubMed ID: 15689621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease.
    Lynch PJ; Tong J; Lehane M; Mallet A; Giblin L; Heffron JJ; Vaughan P; Zafra G; MacLennan DH; McCarthy TV
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):4164-9. PubMed ID: 10097181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
    Vukcevic M; Broman M; Islander G; Bodelsson M; Ranklev-Twetman E; Müller CR; Treves S
    Anesth Analg; 2010 Jul; 111(1):185-90. PubMed ID: 20142353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
    Ta TA; Pessah IN
    Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor.
    Avila G; Dirksen RT
    J Gen Physiol; 2001 Sep; 118(3):277-90. PubMed ID: 11524458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse.
    Yang T; Riehl J; Esteve E; Matthaei KI; Goth S; Allen PD; Pessah IN; Lopez JR
    Anesthesiology; 2006 Dec; 105(6):1164-75. PubMed ID: 17122579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants.
    Miyoshi H; Otsuki S; Mukaida K; Kido K; Sumii A; Ikeda T; Noda Y; Yasuda T; Narasaki S; Kato T; Kamiya S; Horikawa YT; Tsutsumi YM
    Genes (Basel); 2023 Oct; 14(11):. PubMed ID: 38002952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia.
    Schiemann AH; Paul N; Parker R; Pollock N; Bulger TF; Stowell KM
    Anesth Analg; 2014 Feb; 118(2):375-380. PubMed ID: 24361844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
    Eltit JM; Bannister RA; Moua O; Altamirano F; Hopkins PM; Pessah IN; Molinski TF; López JR; Beam KG; Allen PD
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7923-8. PubMed ID: 22547813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing the number of diagnostic mutations in malignant hyperthermia.
    Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
    Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated resting [Ca(2+)](i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR.
    Yang T; Esteve E; Pessah IN; Molinski TF; Allen PD; López JR
    Am J Physiol Cell Physiol; 2007 May; 292(5):C1591-8. PubMed ID: 17182726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Remimazolam and Propofol on Ca
    Watanabe T; Miyoshi H; Noda Y; Narasaki S; Morio A; Toyota Y; Kimura H; Mukaida K; Yasuda T; Tsutsumi YM
    Biomed Res Int; 2021; 2021():8845129. PubMed ID: 33490280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4-chloro-m-cresol in human myotubes.
    Wehner M; Rueffert H; Koenig F; Meinecke CD; Olthoff D
    Cell Calcium; 2003 Aug; 34(2):163-8. PubMed ID: 12810058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A truncation in the RYR1 gene associated with central core lesions in skeletal muscle fibres.
    Rossi D; De Smet P; Lyfenko A; Galli L; Lorenzini S; Franci D; Petrioli F; Orrico A; Angelini C; Tegazzin V; Dirksen R; Sorrentino V
    J Med Genet; 2007 Feb; 44(2):e67. PubMed ID: 17293538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia.
    McKinney LC; Butler T; Mullen SP; Klein MG
    Anesthesiology; 2006 Jun; 104(6):1191-201. PubMed ID: 16732090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.